MAPT and Alzheimer disease: For clinical treatments of AD, a series of drug developments have also been carried out based on the above hypothesis, mainly including the development of cholinesterase inhibitors and immunotherapy, monoclonal antibodies, and amyloid-β peptide (Aβ) and tau protein [7] -targeted therapeutic drugs.